Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1267results about "Receptors for growth factors/regulators" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
PDX1 expressing endoderm
InactiveUS20050266554A1Increase differentiationIncrease productionGastrointestinal cellsDiagnosticsGerm layerCell type
Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Owner:CYTHERA
Biologically active dimerized and multimerized polypeptide fusions
InactiveUS6018026AImprove expression levelMass productionPeptide/protein ingredientsAntibody mimetics/scaffoldsExtracellular StructureA-DNA
Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
Owner:ZYMOGENETICS INC
DNA constructs encoding ligand-binding fusion proteins
Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
Owner:ZYMOGENETICS INC
Dimerized polypeptide fusions
InactiveUS6291646B1Mass productionImprove expression levelPeptide/protein ingredientsAntibody mimetics/scaffoldsExtracellular StructureA-DNA
Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
Owner:ZYMOGENETICS INC
Use of GDF traps to increase red blood cell levels
ActiveUS20100068215A1Improve pharmacokineticsImprove purification effectPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Bispecific chimeric antigen receptors and therapeutic uses thereof
ActiveUS20150038684A1Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellular signallingAntigen receptors
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Owner:SEATTLE CHILDRENS HOSPITAL
Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
InactiveUS20070248605A1Microbiological testing/measurementImmunoglobulins against growth factorsAbnormal tissue growthAntibody
A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.
Owner:FIVE PRIME THERAPEUTICS
Activin-ActRII antagonists and uses for increasing red blood cell levels
ActiveUS20090047281A1Easy to produceReduce expressionCompound screeningApoptosis detectionPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Expression vector for animal cell
InactiveUS7422874B2Increased expression efficiency and levelVectorsSugar derivativesGastrin GeneEvolutionary biology
The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human β-globin 5′ MAR complementary sequence or / and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.
Owner:MOGAM BIOTECH RES INST +1
Novel methods for therapeutic vaccination
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
Owner:BAVARIAN NORDIC AS
Activin-actriia antagonists and uses for treating or preventing breast cancer
ActiveUS20090074768A1Inhibit growthAvoid survivalPeptide/protein ingredientsAntibody mimetics/scaffoldsGynecologyAntagonist
In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
Owner:ACCELERON PHARMA INC
Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins
ActiveUS20130039911A1Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Compositions and methods of treating disease with FGFR fusion proteins
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Owner:FIVE PRIME THERAPEUTICS
Activin-actriia antagonists and uses for promoting bone growth in cancer patients
ActiveUS20090142333A1Promote growthStimulates of mineralizationPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityBone growth
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Owner:ACCELERON PHARMA INC
Method of increasing red blood cell levels or treating anemia in a patient
ActiveUS8058229B2Low affinityReduce impactPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ActiveUS8216997B2Increased formationImprove the level ofOrganic active ingredientsPeptide/protein ingredientsPrimatePhysiology
Owner:ACCELERON PHARMA INC
Activin-actrii antagonists and uses for increasing red blood cell levels
ActiveUS20090163417A1Reduce expressionIncrease redCompound screeningApoptosis detectionPrimateRed Cell
Owner:ACCELERON PHARMA INC
Compositions and methods useful for culturing differentiable cells
Owner:VIACYTE INC
Activin-ActRIIa antagonists and uses for promoting bone growth
ActiveUS20090098113A1Reduce expressionPromote bone growthPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityBone growth
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Owner:ACCELERON PHARMA INC
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ActiveUS8993524B2Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Activin-ActRIIa antagonists and uses for promoting bone growth
ActiveUS20090099086A1Reduce expressionPromote bone growthPeptide/protein ingredientsAntibody mimetics/scaffoldsIncreased Bone DensityCancer research
Owner:ACCELERON PHARMA INC
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS20100028331A1Easy to produceReduce expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Muteins of fibroblast growth factor 21
The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
Owner:ELI LILLY & CO
Antagonists of actriib and uses for increasing red blood cell levels
InactiveUS20100028332A1Distribution moreMany formatsPeptide/protein ingredientsAntibody mimetics/scaffoldsRed CellAntagonist
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Methods for increasing thermogenic adipocytes
ActiveUS8178488B2High expressionIncreasing thermogenic adipocytesOrganic active ingredientsPeptide/protein ingredientsNODALDisease
In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Owner:ACCELERON PHARMA INC
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
Masking ligands for reversibly concealing the antigen-binding site of an antibody comprise epitopes of the antibody and a cleavable linker. Methods for making masking ligands comprise joining at least two copies of the epitope of an antibody to a cleavable polypeptide linker.
Owner:TEGOPHARM CORP
Use of gdf traps to increase red blood cell levels
ActiveUS20120015877A1Distribution moreMany formatsPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
Owner:ACCELERON PHARMA INC
Targeted TGFβ inhibitors
ActiveUS9676863B2Effective therapyNervous disorderPeptide/protein ingredientsAntigenAntigen Binding Fragment
This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
Owner:MERCK PATENT GMBH
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
ActiveUS9447194B2Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellularAntigen receptors
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Owner:SEATTLE CHILDRENS HOSPITAL
EGF receptor epitope peptides and uses thereof
ActiveUS20050255555A1Peptide/protein ingredientsGenetic material ingredientsEpitopeAbnormal tissue growth
The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
Owner:COMMONWEALTH SCI & IND RES ORG +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com